SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community discusses recent news and potential impacts from political decisions. Community members are focused on trade negotiations and tariff implications, as well as commentary around political figures and events. Broader discussions include market dynamics and potential financial strategies related to the stock.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss its AI-powered biometric platform being deployed at Chicago O'Hare International Airport, sparking speculation about further airport security contracts and a potential TSA deal. The community is also focused on the company's large short interest and upcoming earnings, with some anticipating a squeeze. Bullish sentiment is fueled by the company's advancements in AI and its potential for significant growth within the national security sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

The crypto asset $BALLIN is gaining attention, particularly within the Phantom Wallet community, with many highlighting its potential for significant gains. Community members are encouraged to buy and hold, emphasizing the opportunity for early entry and substantial profits. The focus is on strong upward momentum and the potential for a breakout.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies ($LUMN) is trending amid discussions about its role in AI infrastructure, particularly following a $200M deal with Palantir ($PLTR) to boost enterprise AI. Community members highlight Lumen's fiber optic network and partnerships with hyperscalers as key assets for AI data connectivity. Some are speculating on future earnings and potential government stakes in the company.

Mkango Resources Ltd.

Mkango Resources is trending amid discussions about rare earth elements and critical mineral demand. Community members are pointing to supply chain developments and broader interest in the sector as potential catalysts. Some traders are attributing recent price action to warrant exercises while others see it as a temporary cooling off period before another potential move.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is experiencing increased volatility, with community members actively discussing potential breakouts and resistance levels. Recent market activity and whale movements are sparking conversations about whether ETH can sustain its gains. Broader narratives around tokenization and potential ETF staking approvals are also influencing sentiment, adding to the current price swings.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to upcoming presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting in November, where the company will share insights from its enLIGHTEN Discovery Platform and additional data from the CAN-2409 program. The community is also discussing the company's prioritization of prostate cancer and NSCLC, as well as potential partnerships for its pancreatic cancer treatment. Bullish investors are optimistic about the long-term potential, citing the large market opportunities and the company's experienced leadership team.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont (NEM) is trending due to recent earnings, mixed reactions to the CEO's conference call, and fluctuating gold prices, leading to debate on its short-term performance. The community is discussing whether NEM's stock drop is a buying opportunity or a sign of deeper issues, with some citing its strong fundamentals and others pointing to concerns about cash flow and CEO communication. Despite mixed sentiment, Newmont's long-term outlook remains positive, driven by solid earnings growth expectations and a potentially undervalued stock price in the precious metals mining sector.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as the community discusses its strong pharmaceutical pipeline and potential acquisitions, particularly after positive trial results and an increased focus on neuroscience. Bullish sentiment is fueled by rising sales of Skyrizi and Rinvoq, offsetting Humira's decline, alongside speculation about potential M&A activity in the sector. The community is closely watching upcoming earnings and price target adjustments by analysts.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals (KALV) announced on Friday that the European Commission (EC) and the Swiss Agency for Therapeutic Products, Swissmedic, have approved its Ekterly for the symptomatic treatment of acute attacks of hereditary angioedema (HAE).Ekterly was approved by both agencies for the treatment of adults and adolescents aged 12 years and older with HAE. It is the first and only oral on-demand treatment for HAE in the two regions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-european-commission-and">said</a>.Shares of the company traded lower by 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALV">KalVista</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘normal’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_12_33_07_PM_png_055493ce17.webp" alt="KALV's Sentiment Meter and Message Volume as of 12:33 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>KALV's Sentiment Meter and Message Volume as of 12:33 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock rallying to $22 in 12 months.<stembedurl>https://stocktwits.com/PokerMunkee/message/629305223</stembedurl>Another opined that the stock has a lot of “potential and great setup.”<stembedurl>https://stocktwits.com/Shakattack31/message/629258146</stembedurl>“With our U.S. launch progressing well and approvals now secured in the U.K., EU, and Switzerland, we look forward to bringing this innovation to more people living with HAE, beginning with our first European launch in Germany,” CEO Ben Palleiko said. The company expects to launch Ekterly in Germany in the fourth quarter and in Switzerland in the second half of 2026.The recent approvals are based on the results of a late-stage trial where Ekterly achieved significantly faster symptom relief, reduction in attack severity, and attack resolution than placebo. The results also showed that the drug was well-tolerated, with a safety profile similar to that of the placebo.The EC approval applies to all 27 EU member states as well as Iceland, Liechtenstein, and Norway. In August, the European Medicines Agency also granted Ekterly 10 years of market exclusivity.Hereditary angioedema (HAE) is a rare genetic disease caused by a deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Ekterly <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-gets-fda-approval-for-drug-in-treating-swelling-disorder/chFtmFCR57B">received</a> approval from the U.S. Food and Drug Administration for the treatment of HAE in July.KALV stock is up by about 61% this year and by about 24% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/emergent-biosolutions-stock-rises-after-receiving-fresh-international-purchase-orders/chD3729R3Tf">Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

Ekterly is now the first and only oral on-demand treatment for hereditary angioedema in the two regions, the company said. 

Equity

Ekterly is now the first and only oral on-demand treatment for hereditary angioedema in the two regions, the company said. 


KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?

KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

KalVista Pharmaceuticals, Inc. (KALV) on Monday said that the U.S. Food and Drug Administration (FDA) has approved its drug Ekterly for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older.<a href="https://stocktwits.com/symbol/KALV">KalVista</a>’s shares were up over 17% in pre-market trading.Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.Ekterly is the first and only oral on-demand treatment for HAE, KalVista <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr">said</a>, setting it apart from other on-demand HAE treatment options approved in the U.S., which require intravenous or subcutaneous administration.Even with the use of long-term prophylaxis as a preventative therapy, most people living with HAE continue to have unpredictable attacks and require on-demand access to medication, the company added.KalVista will launch Ekterly in the U.S. immediately, and physicians can begin writing prescriptions on Monday.The approval was based on results from a late-stage study in 136 patients, showing that Ekterly achieved significantly faster symptom relief, a reduction in attack severity, and an increase in attack resolution compared to the placebo. The results also showed that the drug was well-tolerated, with a safety profile similar to that of the placebo.A later study also showed that Ekterly enabled patients to treat attacks in a median of 10 minutes following onset.On Stocktwits, retail sentiment around KalVista jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_8_56_04_AM_png_8e1123c17a.webp" alt="KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="67"><figcaption>KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the stock hitting as high as $50 upon the news.<stembedurl>https://stocktwits.com/fzriderz/message/620039415</stembedurl>KALV stock is up by over 41% this year and down by about 2% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/shell-signals-earnings-dip-in-trading-in-q2-but-refining-margin-to-improve/chFthjLR5PR">Shell Signals Earnings Dip In Trading In Q2, But Refining Margin To Improve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration. 

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care...

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy...

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVistas board of directors granted fifty-two newly-hired employees inducement options to purchase...

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japans Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVistas board of directors granted nine newly-hired employees inducement options to purchase an...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	-$1.03	--	--	N/A
Q1 '25	-$0.95	-$1.12	-17.48%	MISSED
Q4 '24	-$0.80	-$0.99	-23.92%	MISSED
Q3 '24	-$0.87	-$0.92	-6.24%	MISSED
Q2 '24	-$0.91	-$0.91	--	EXPECTED

KALV
KalVista Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '25

Historical Earnings

Latest KALV News

KALVKalVista Pharmaceuticals Inc